Please ensure Javascript is enabled for purposes of website accessibility

Is Trulieve a Buy After Acquiring Harvest Health & Recreation?

By Eric Volkman - Updated Jun 23, 2021 at 9:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It wasn't exactly a dirt cheap purchase, after all.

$2.1 billion is hardly pocket change. But ambitious Florida marijuana company Trulieve Cannabis (TCNNF 2.03%) is ponying up such a pile -- of its stock, anyway -- to buy West Coast peer Harvest Health & Recreation (HRVSF).

As he reveals in this segment from Motley Fool Live, veteran Fool contributor Eric Volkman thinks this is money (well, technically, company stock) well spent. He explains his reasons why with healthcare and cannabis bureau chief Corinne Cardina. This video was recorded on May 21.

Corinne Cardina: Would you say that Trulieve looks like a buy based on [the Harvest] acquisition?

Eric Volkman: Yeah. It's not a cheap stock, and it's not a cheap stock because Trulieve until now it's following Harvest, has been one of the very rare, and very special, profitable multi-state operators (MSOs). They are barely multi-state. Outside of Florida -- until Harvest again -- they had only small operations in these places like Pennsylvania.

But yeah, they were profitable, not always and because they were one of the few profitable MSOs, investors really latched onto them. They're not cheap. But what I like about Trulieve is they are very good at maintaining and even expanding their market share in Florida. They know their market very well, and I think their strategy up until now has been sensible to places that they ventured, places like Pennsylvania that are limited licensed states where you have only a small number of licenses and therefore, theoretically low competition.

I think Trulieve is pricey, but if any marijuana stock is worth their pricing it's Trulieve. That profitability is going to be on the hook with Harvest because Harvest, like a lot of its other peers, is consistently unprofitable. In their last reported quarter, Q1, they lost almost $23 million. It's not the end of the world, but with the combined company, it's going to affect the results.

Having said that, they are growing in terms of the top line. In their quarter, they made almost $89 million and that was on a quarter-by-quarter basis 27% higher, which is admirable for the most recent set of results it's higher and it was slightly more than double year-on-year. I think Trulieve is getting one of the better assets and again, I like the geographical, complimentary nature of it.

Corinne Cardina has no position in any of the stocks mentioned. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Trulieve Cannabis Corp. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
TCNNF
$13.07 (2.03%) $0.26
Harvest Health & Recreation Inc. Stock Quote
Harvest Health & Recreation Inc.
HRVSF

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.